Our Distinctive Approach Drives Success PureTech's Proven Expertise 8 1 References in this presentation to "Wholly Owned Programs" refer to the Company's six therapeutic candidates (LYT-100, LYT-200, LYT-300, LYT-310, LYT-510, and LYT-503/IMB-150), lymphatic and inflammation platforms and potential future therapeutic candidates and platforms that the Company may develop or obtain. References to "Wholly Owned Pipeline" refer to LYT-100, LYT-200, LYT-300, LYT-310, LYT-510, and LYT-503/IMB-150. On July 23, 202 ...

PURETECH GIVING LIFE TO SCIENCE® August 2022 BRAIN IMMUNE GUT Important Information The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by PureTech Health plc (the "Company"). The information in the Presen ...

Financial Performance - Total revenue for the six months ended June 30, 2022, was $7.0 million, compared to $5.8 million for the same period in 2021, marking an increase of approximately 19.5%[126]. - The company incurred a loss of $23.5 million for the period ended June 30, 2022, compared to a loss of $77.6 million for the same period in 2021, indicating a reduction in losses[126]. - Net loss for the six months ended June 30, 2022, was $28,344,000, compared to a net loss of $75,395,000 for the same period in 2021, representing a 62.4% improvement[133]. - Total comprehensive income for the period ended June 30, 2022, was a loss of $28,880,000, compared to a loss of $77,553,000 in 2021, reflecting a 62.9% reduction in comprehensive losses[133]. - The Group reported a net loss of $23.472 million for the six months ended June 30, 2022, compared to a net loss of $28.880 million in the same period of 2021, showing an improvement of 18.9%[159]. Cash Flow and Liquidity - As of June 30, 2022, the company had consolidated cash and cash equivalents of $365.9 million, down from $465.7 million as of June 30, 2021, representing a decrease of approximately 21.4%[116][128]. - Net cash used in operating activities for the six months ended June 30, 2022, was $87.2 million, an increase of $21.9 million compared to $65.4 million for the same period in 2021, reflecting higher operating losses primarily due to increased research and development activities[119]. - Cash flows from operating activities resulted in a net cash used of $87,249,000 for the first half of 2022, compared to $65,366,000 in the same period of 2021, indicating a 33.4% increase in cash outflow[133]. - Cash and cash equivalents at the end of the period were $365,910,000, down from $439,766,000 at the end of June 2021, marking a decrease of 16.7%[134]. - The company expects its existing financial assets will be sufficient to fund operations and capital expenditures into the first quarter of 2026, despite ongoing net operating losses typical for pre-revenue biotechnology companies[122]. Operating Expenses - Operating loss for the six months ended June 30, 2022, was $101.2 million, compared to a loss of $68.1 million for the same period in 2021, indicating a significant increase in operating expenses[126]. - Research and development expenses totaled $84.579 million for the six months ended June 30, 2022, compared to $20.877 million in 2021, indicating a significant increase of 304.5%[159]. - Total operating expenses reached $73.92 million, up from $31.58 million, indicating a year-over-year increase of 134%[160]. Investments and Fair Value - The company experienced a gain on investments held at fair value of $59,019,000 in 2022, contrasting with a loss of $74,415,000 in 2021, indicating a significant turnaround[133]. - The fair value of investments held at fair value decreased to $367.95 million as of June 30, 2022, down from $493.89 million at the beginning of the year, reflecting a decline of 25.5%[161]. - The Group recorded a loss of $29.9 million on investments held at fair value during the six months ended June 30, 2022, which was reflected in the Condensed Consolidated Statements of Comprehensive Income/(Loss)[233]. - The balance of investments held at fair value as of June 30, 2022, was $142.394 million, down from $239.533 million at the beginning of the year, after accounting for a loss of $(30.217) million[234]. Shareholder Equity and Stock Activity - The total equity of the parent company as of June 30, 2022, was $576,024,000, compared to $561,372,000 at the end of June 2021, reflecting a 2.6% increase[132]. - The company commenced a $50 million share repurchase program, with the first tranche amounting to $25 million[217]. - As of June 30, 2022, the company had 288,611,120 common shares outstanding, including 2,010,269 shares repurchased and held in treasury[219]. - The company reported a cash outflow of $4,267,000 from the purchase of treasury stock in 2022, with no such outflow reported in 2021[133]. Tax and Financing - The Group recorded a consolidated tax provision of $(32.5) million benefit for the six months ended June 30, 2022, representing an effective tax rate of 58.1%[277]. - The company incurred finance costs of $56,320,000 in the first half of 2022, compared to a net income of $16,252,000 in the same period of 2021, indicating a significant shift in financial performance[133]. - Total finance income for the six months ended June 30, 2022, was $630,000, compared to $119,000 in 2021, representing a significant increase of 429%[209]. - The total finance costs decreased from $2,755,000 in 2021 to $1,961,000 in 2022, a reduction of approximately 29%[209]. Management and Compensation - Key management personnel compensation for the six months ended June 30, 2022, totaled $(337) thousand, reflecting a net income in share-based compensation due to a decrease in RSU value[266]. - The Group incurred share-based payment expenses of $3.6 million for the six months ended June 30, 2022, down from $5.6 million in the same period of 2021[189]. - The Group's share-based payment expense for stock options was $4.5 million for the six months ended June 30, 2022[203].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | (Mark One) | | | --- | --- | | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2021 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the transition period from to ...

As filed with the Securities and Exchange Commission on April 15, 2021. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | (Mark One) | | | --- | --- | | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2020 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...